本帖最后由 老马 于 2012-1-13 21:20 编辑 . U+ P( h7 b4 i) h$ g
0 x1 R% s& M" C- P. w' R$ @爱必妥和阿瓦斯丁的比较/ Y) l5 ~* |# {1 d- c1 B
2 Q9 m5 i" G" c+ u1 l( W
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
/ V# s( _; p9 w3 k
% {" }$ e9 L i- ?4 o W3 E5 [! c
2 o6 X+ X# M! i3 l4 ~0 q
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 k& _9 ]( V' v: a6 c# A
==================================================
0 r% z/ x7 K3 V2 a% ^9 ROverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 |: C* @+ F# Z# T/ ^# WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# H5 I' c2 o; Y- _# z! E; r0 r$ n) m
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* M& G0 `# Y' \
|
显身卡
3 S7 ~$ g( ]3 a, r) Z1 m
